FY2026 · ended Mar 31, 2026 · Revenue $19.53M, +36.7% YoY · Filed Jun 16, 2026
Sonoma Pharmaceuticals, Inc. (SNOA) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2026, which ended Mar 31, 2026, it reported revenue of $19.5 million and a net loss of $3.2 million. Free cash flow was -$4.1 million. As of Jun 30, 2026 it held $5.3 million in cash and investments and $739,000 in total debt.
Revenue (TTM)
$21.92M
+47.0% vs year-ago TTM
Net income (TTM)
$-2.26M
+36.3% vs year-ago TTM
Operating cash flow (TTM)
$-2.57M
-115.5% vs year-ago TTM
Free cash flow (TTM)
$-2.65M
-93.5% vs year-ago TTM
EPS (TTM)
$-1.02
+59.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
4.79M
+191.3% vs prior year
Net cash
$4.60M
as of Jun 30, 2026
Operating margin
-6.4%
FY 2027
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- SNOA (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Boulder, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1367083
- Former names
- Oculus Innovative Sciences, Inc. (until Dec 2, 2016)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2026 Mar 31, 2026 |
FY 2025 Mar 31, 2025 |
FY 2024 Mar 31, 2024 |
FY 2023 Mar 31, 2023 |
FY 2022 Mar 31, 2022 |
|---|---|---|---|---|---|
| Revenue | $19.5M | $14.3M | $12.7M | $13.3M | $12.6M |
| Operating income | -$2.5M | -$3.7M | -$4.7M | -$4.6M | -$5.9M |
| Net income | -$3.2M | -$3.5M | -$4.8M | -$5.2M | -$5.1M |
| Diluted EPS | -$1.89 | -$2.79 | -$10.63 | -$1.52 | — |
| Operating cash flow | -$3.9M | -$88,000 | -$2.4M | -$6.2M | -$4.2M |
| Free cash flow | -$4.1M | -$168,000 | -$2.4M | -$6.4M | -$4.4M |
| Total assets | $14.0M | $13.7M | $14.7M | $16.2M | $18.8M |
| Total liabilities | $10.9M | $9.3M | $8.6M | $8.3M | $10.1M |
| Stockholders' equity | $3.1M | $4.4M | $6.1M | $8.0M | $8.7M |
| Cash and investments | $2.4M | $5.4M | $3.1M | $3.8M | $7.4M |
| Total debt | $842,000 | $305,000 | $608,000 | $418,000 | $559,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change
|
Oct 6, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Sep 17, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 19, 2026 | Aug 19, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jun 18, 2026 | Jun 18, 2026 |
| 10-K | Annual report | Jun 16, 2026 | Mar 31, 2026 |
All 977 Sonoma Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.